Cited 45 times in
Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 박수정 | - |
dc.date.accessioned | 2015-01-06T16:55:33Z | - |
dc.date.available | 2015-01-06T16:55:33Z | - |
dc.date.issued | 2014 | - |
dc.identifier.issn | 1873-9946 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/99036 | - |
dc.description.abstract | BACKGROUND/AIMS: The effect of immunosuppressants on the efficacy of a variety of vaccines is a controversial issue in patients with inflammatory bowel disease (IBD). In this study we determined whether specific immunosuppressants impair the serological response to the standard 23-valent pneumococcal polysaccharide vaccine (PPSV23) in a large cohort of patients with Crohn's disease (CD). METHODS: This was a multi-center, prospective observational study of adult patients with CD at 15 academic teaching hospitals in Korea. The study population received one intramuscular injection of PPSV23. Anti-pneumococcal IgG antibody titers were measured by immunoassay prior to and 4weeks after vaccination. All vaccination-related adverse events and the effect of the vaccine on disease activity were also evaluated. RESULTS: The overall serological response rate was 67.5% (133/197). The serological response rate was significantly lower in patients on anti-tumor necrosis factor (anti-TNF) therapy (50.0% on anti-TNF alone; 58.0% on anti-TNF combined with an immunomodulator, IM) than patients on 5-aminosalicylate (78.4%; all P-values vs. 5-aminosalicylate<0.05); 45.6% (41/90) of patients on anti-TNF therapy were not protected against PPSV23. IM did not affect the immunologic response to the vaccine. Female gender and anti-TNF therapy were significant predictors of non-response to the vaccine (odds ratio [OR] 2.316, P=0.015; OR 2.582, P=0.048, respectively). Vaccination was generally safe and tolerated by all patients. CONCLUSIONS: Patients with CD on anti-TNF therapy are at significant risk of an inadequate response to PPSV23. The pneumococcal vaccination strategy should be optimized for patients with CD on anti-TNF therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 384~391 | - |
dc.relation.isPartOf | JOURNAL OF CROHNS & COLITIS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adult | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | Crohn Disease/blood | - |
dc.subject.MESH | Crohn Disease/drug therapy* | - |
dc.subject.MESH | Crohn Disease/immunology* | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hospitals, Teaching | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunoglobulin G/blood* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Pneumococcal Vaccines/administration & dosage* | - |
dc.subject.MESH | Prospective Studies | - |
dc.subject.MESH | Republic of Korea | - |
dc.subject.MESH | Tumor Necrosis Factor-alpha/antagonists & inhibitors* | - |
dc.title | Patients with Crohn's disease on anti-tumor necrosis factor therapy are at significant risk of inadequate response to the 23-valent pneumococcal polysaccharide vaccine | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | Chang Kyun Lee | - |
dc.contributor.googleauthor | Hyun-Soo Kim | - |
dc.contributor.googleauthor | Byong Duk Ye | - |
dc.contributor.googleauthor | Kang-Moon Lee | - |
dc.contributor.googleauthor | You Sun Kim | - |
dc.contributor.googleauthor | Sang Youl Rhee | - |
dc.contributor.googleauthor | Hyo-Jong Kim | - |
dc.contributor.googleauthor | Suk-Kyun Yang | - |
dc.contributor.googleauthor | Won Moon | - |
dc.contributor.googleauthor | Ja-Seol Koo | - |
dc.contributor.googleauthor | Suck-Ho Lee | - |
dc.contributor.googleauthor | Geom Seog Seo | - |
dc.contributor.googleauthor | Soo Jung Park | - |
dc.contributor.googleauthor | Chang Hwan Choi | - |
dc.contributor.googleauthor | Sung-Ae Jung | - |
dc.contributor.googleauthor | Sung Noh Hong | - |
dc.contributor.googleauthor | Jong Pil Im | - |
dc.contributor.googleauthor | Eun Soo Kim | - |
dc.identifier.doi | 10.1016/j.crohns.2013.09.022 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A01539 | - |
dc.relation.journalcode | J01359 | - |
dc.identifier.eissn | 1876-4479 | - |
dc.identifier.pmid | 24144611 | - |
dc.identifier.url | http://www.sciencedirect.com/science/article/pii/S1873994613003516 | - |
dc.subject.keyword | Crohn's disease | - |
dc.subject.keyword | Immunosuppressive agents | - |
dc.subject.keyword | Inflammatory bowel disease | - |
dc.subject.keyword | Pneumococcal vaccine | - |
dc.contributor.alternativeName | Park, Soo Jung | - |
dc.contributor.affiliatedAuthor | Park, Soo Jung | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 8 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 384 | - |
dc.citation.endPage | 391 | - |
dc.identifier.bibliographicCitation | JOURNAL OF CROHNS & COLITIS, Vol.8(5) : 384-391, 2014 | - |
dc.identifier.rimsid | 50224 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.